KALA BIO, Inc. (KALA)
(Real Time Quote from BATS)
$7.89 USD
+0.44 (5.91%)
Updated Aug 5, 2025 03:08 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KALA 7.89 +0.44(5.91%)
Will KALA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KALA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KALA
Zacks.com featured highlights include KALA, Graham, Arq and Hawkins
Analyst Coverage Sparks Interest in These 4 Stocks Amid Volatility
KALA: What are Zacks experts saying now?
Zacks Private Portfolio Services
KALA BIO (KALA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
KALA BIO (KALA) Moves to Strong Buy: Rationale Behind the Upgrade
KALA BIO (KALA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Other News for KALA
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Kala Pharmaceuticals (KALA) Receives Buy Rating from Ladenburg | KALA Stock News
Kala Pharmaceuticals initiated with bullish view at Ladenburg, here's why
KALA Completes Patient Enrollment in Phase 2b CHASE Trial for KPI-012 | KALA Stock News
Kala completes patient enrollment for CHASE Phase 2 clinical trial